Cargando…
Systematic Assessment of Fragment Identification for Multitarget Drug Design
Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment‐based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment‐based multiple ligand discovery, we have employ...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049054/ https://www.ncbi.nlm.nih.gov/pubmed/33283450 http://dx.doi.org/10.1002/cmdc.202000858 |
_version_ | 1783679355692515328 |
---|---|
author | Brunst, Steffen Kramer, Jan S. Kilu, Whitney Heering, Jan Pollinger, Julius Hiesinger, Kerstin George, Sven Steinhilber, Dieter Merk, Daniel Proschak, Ewgenij |
author_facet | Brunst, Steffen Kramer, Jan S. Kilu, Whitney Heering, Jan Pollinger, Julius Hiesinger, Kerstin George, Sven Steinhilber, Dieter Merk, Daniel Proschak, Ewgenij |
author_sort | Brunst, Steffen |
collection | PubMed |
description | Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment‐based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment‐based multiple ligand discovery, we have employed a large fragment library for comprehensive screening on five targets chosen from proteins for which multitarget ligands have been successfully developed previously (soluble epoxide hydrolase, leukotriene A4 hydrolase, 5‐lipoxygenase, retinoid X receptor, farnesoid X receptor). Differential scanning fluorimetry served as primary screening method before fragments hitting at least two targets were validated in orthogonal assays. Thereby, we obtained valuable fragment leads with dual‐target engagement for six out of ten target combinations. Our results demonstrate the applicability of fragment‐based approaches to identify starting points for polypharmacological compound development with certain limitations. |
format | Online Article Text |
id | pubmed-8049054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80490542021-04-20 Systematic Assessment of Fragment Identification for Multitarget Drug Design Brunst, Steffen Kramer, Jan S. Kilu, Whitney Heering, Jan Pollinger, Julius Hiesinger, Kerstin George, Sven Steinhilber, Dieter Merk, Daniel Proschak, Ewgenij ChemMedChem Communications Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment‐based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment‐based multiple ligand discovery, we have employed a large fragment library for comprehensive screening on five targets chosen from proteins for which multitarget ligands have been successfully developed previously (soluble epoxide hydrolase, leukotriene A4 hydrolase, 5‐lipoxygenase, retinoid X receptor, farnesoid X receptor). Differential scanning fluorimetry served as primary screening method before fragments hitting at least two targets were validated in orthogonal assays. Thereby, we obtained valuable fragment leads with dual‐target engagement for six out of ten target combinations. Our results demonstrate the applicability of fragment‐based approaches to identify starting points for polypharmacological compound development with certain limitations. John Wiley and Sons Inc. 2021-02-04 2021-04-08 /pmc/articles/PMC8049054/ /pubmed/33283450 http://dx.doi.org/10.1002/cmdc.202000858 Text en © 2020 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Communications Brunst, Steffen Kramer, Jan S. Kilu, Whitney Heering, Jan Pollinger, Julius Hiesinger, Kerstin George, Sven Steinhilber, Dieter Merk, Daniel Proschak, Ewgenij Systematic Assessment of Fragment Identification for Multitarget Drug Design |
title | Systematic Assessment of Fragment Identification for Multitarget Drug Design |
title_full | Systematic Assessment of Fragment Identification for Multitarget Drug Design |
title_fullStr | Systematic Assessment of Fragment Identification for Multitarget Drug Design |
title_full_unstemmed | Systematic Assessment of Fragment Identification for Multitarget Drug Design |
title_short | Systematic Assessment of Fragment Identification for Multitarget Drug Design |
title_sort | systematic assessment of fragment identification for multitarget drug design |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049054/ https://www.ncbi.nlm.nih.gov/pubmed/33283450 http://dx.doi.org/10.1002/cmdc.202000858 |
work_keys_str_mv | AT brunststeffen systematicassessmentoffragmentidentificationformultitargetdrugdesign AT kramerjans systematicassessmentoffragmentidentificationformultitargetdrugdesign AT kiluwhitney systematicassessmentoffragmentidentificationformultitargetdrugdesign AT heeringjan systematicassessmentoffragmentidentificationformultitargetdrugdesign AT pollingerjulius systematicassessmentoffragmentidentificationformultitargetdrugdesign AT hiesingerkerstin systematicassessmentoffragmentidentificationformultitargetdrugdesign AT georgesven systematicassessmentoffragmentidentificationformultitargetdrugdesign AT steinhilberdieter systematicassessmentoffragmentidentificationformultitargetdrugdesign AT merkdaniel systematicassessmentoffragmentidentificationformultitargetdrugdesign AT proschakewgenij systematicassessmentoffragmentidentificationformultitargetdrugdesign |